

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



RICI HEALTHCARE HOLDINGS LIMITED

瑞慈醫療服務控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1526)

(1) RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR; (2) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR; AND (3) CHANGE IN COMPOSITION OF BOARD COMMITTEE

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Rici Healthcare Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Dr. Wang Yong (“**Dr. Wang**”) has tendered his resignation as an independent non-executive Director and a member of the audit committee of the Company (the “**Audit Committee**”) with effect from December 29, 2025 in order to devote more time to focus on his other business commitments.

Dr. Wang has confirmed that he has no disagreement with the Board and the Company and there are no other matters in respect of his resignation which need to be brought to the attention of The Stock Exchange of Hong Kong Limited and the shareholders of the Company.

The Board would like to express its sincere appreciation to Dr. Wang for his valuable contribution to the Company during the tenure of his service as an independent non-executive Director.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board is pleased to announce it has appointed Mr. Tian Wenguo (“**Mr. Tian**”) as an independent non-executive Director of the Company to fill the casual vacancy, and a member of the Audit Committee, with effect from December 29, 2025. As such, pursuant to the second amended and restated memorandum and articles of association of the Company (the “**Articles of Association**”), Mr. Tian shall hold office until the first general meeting of the Company after his appointment, being the forthcoming annual general meeting of the Company (the “**AGM**”), and be subject to re-election by the shareholders of the Company (the “**Shareholders**”) at the AGM.

The biographical details of Mr. Tian are set out as follows:

Mr. Tian Wenguo, aged 56, possesses extensive experience in the telecommunications industry, with over 30 years of management expertise in the field. Since April 2018, Mr. Tian has served as the chairman of Shidai Yuning (Shenzhen) Technology Co., Ltd. (時代雲英(深圳)科技有限公司). Previously, Mr. Tian worked at ZTE Corporation, where he successively served the roles of manager of the Chongqing office and general manager of the Southwest region at ZTE Corporation from 1996 to 2002, senior vice president and general manager of the Sales Division II from 2002 to 2005, executive vice president in charge of the marketing and operations system from 2005 to 2007, executive vice president in charge of the marketing system from 2007 to 2008, executive vice president in charge of the product marketing system from 2008 to 2010, executive vice president in charge of the logistics system from 2010 to 2012, executive vice president in charge of global sales and engineering services from 2012 to 2015, and person-in-charge of the new energy sector from 2016 to 2017. Subsequently, from 2017 to 2018, Mr. Tian served as the chairman of Shenzhen ZTE International Investment Limited (深圳市中興國際投資有限公司), Sanya ZTE International Investment Co., Ltd. (三亞中興國際投資有限公司), and Tianjin ZTE International Investment Company Limited (天津中興國際投資有限公司).

Mr. Tian graduated from Harbin Institute of Technology in 1991, where he obtained his bachelor’s degree majoring in Electromagnetic Measurement and Instrumentation. From 2005 to 2006, he completed his EMBA program at Tsinghua University and obtained a master’s degree in Business Administration.

Mr. Tian's appointment has been recommended by members of the nomination committee of the Company and approved by the Board. Pursuant to the letter of appointment between Mr. Tian and the Company, the term of service of Mr. Tian shall be three years commencing on December 29, 2025, subject to retirement by rotation and re-election at the AGM in accordance with the Articles of Association, and Mr. Tian will be entitled to a director's fee of HK\$220,000 per annum, which has been recommended by the remuneration committee of the Company and approved by the Board with reference to, among other things, (i) his duties and responsibilities within the Company; (ii) the prevailing market conditions; and (iii) the continuous expansion of the business scale and continuously heightening requirements on corporate governance of the Company over recent years.

Mr. Tian has confirmed that (i) he has satisfied all the criteria for independence as set out in Rule 3.13(1) to (8) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"); (ii) he has no past or present financial or other interest in the business of the Group or any connection with any core connected person (as defined in the Listing Rules) of the Company; and (iii) there are no other factors that may affect his independence at the time of his appointment.

Save as disclosed above, as at the date of this announcement, Mr. Tian (i) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) has not held any other positions with the Company or other members of the Group; (iii) has not been a director of any public company, the securities of which are listed on any securities market in Hong Kong or overseas, in the last three years; (iv) does not have any other major appointments and professional qualifications; (v) does not have any relationship with any Director, senior management or substantial or controlling shareholders of the Company; (vi) has no other information that needs to be disclosed pursuant to paragraphs (h) to (v) of Rule 13.51(2) of the Listing Rules; and (vii) has no other matter that needs to be brought to the attention of the Shareholders.

The Board would like to take this opportunity to welcome Mr. Tian for joining the Company.

CHANGE IN COMPOSITION OF BOARD COMMITTEE

The Board further announces that with effect from December 29, 2025, as Dr. Wang has resigned as a member of the Audit Committee and Mr. Tian has been appointed as a member of the Audit Committee, the Audit Committee will comprise Ms. Wong Sze Wing (chairman), Mr. Jiang Peixing and Mr. Tian.

By order of the Board
Rici Healthcare Holdings Limited
Fang Yixin
Chairman and Chief Executive Officer

Hong Kong, December 29, 2025

As at the date of this announcement, the Board comprises four executive Directors, namely Dr. Fang Yixin, Dr. Mei Hong, Mr. Fang Haoze and Ms. Lin Xiaoying; and three independent non-executive Directors, namely Mr. Jiang Peixing, Ms. Wong Sze Wing and Mr. Tian Wenguo.